ReShape Lifesciences Inc

RSLS | Healthcare | NASDAQ
$3.92
+0.72 (+22.50%)

Key Metrics

Market Cap
$2.34M
P/E Ratio
0.00
EPS
$-830.44
Beta
N/A
Dividend Yield
N/A
ROE
-493.26%
Current Ratio
1.94

Company Information

Industry
Medical Devices

About ReShape Lifesciences Inc

ReShape Lifesciences Inc a medical device company provides products and services that manages and treat obesity and metabolic diseases in the United States Australia Europe and internationally The companys product portfolio includes LapBand System a minimally invasive longterm treatment of severe obesity and more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy and ReShape Vest system an investigational minimally invasive laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach or bypassing any portion of the gastrointestinal tract It also offers ReShapeCare virtual health coaching program a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weightloss patients and ReShape Diabetes BlocStim Neuromodulation a technology that is in preclinical development for the treatment of type 2 diabetes mellitus In addition the company provides Obalon Balloon System a swallowable capsule used to track and display the location of the balloon during placement The company was formerly known as EnteroMedics Inc and changed its name to ReShape Lifesciences Inc in 2017 ReShape Lifesciences Inc was incorporated in 2002 and is headquartered in San Clemente California

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-11-18 $-29.42 $-0.11 26,642.7%
2025-04-04 $-47.25 $-101.50 +-53.4%
2024-11-14 $-3.11 $-5.80 +-46.4%
2024-08-14 $-3.49 $-6.96 +-49.9%

Financial Ratios (TTM)

Gross Margin
62.39%
Operating Margin
-347.70%
Net Margin
-274.45%
ROA
-163.40%
Price to Book
0.45
Price to Sales
0.56